60 Degrees shares surge 15.89% intraday after FY2025 revenue jumps 65% to $1.0M and clinical progress fuels optimism.

60 Degrees Pharmaceuticals surged 15.89% intraday following the announcement of its FY 2025 annual results, which showed a 65% increase in net product revenues to $1.005 million. The company also reported improved net losses and key business developments, including expanded access cures for relapsing babesiosis, new pharmacy partnerships with GoodRx and Runway Health, and progress in clinical trials. The stock's sharp rise appears driven by positive investor reaction to the revenue growth and strategic momentum in both clinical and commercial operations.